- Cathay International, an operator and investor in the healthcare sector in the People's Republic of China, has announced an investment made by its subsidiary, Lansen Pharmaceutical.

The 50.56% owned subsidiary's own indirect wholly owned subsidiary, Ningbo Lansen Medibeauty Tech Limited, has entered into an equity transfer agreement for the purchase of a 20% equity interest in Tianjin Robustnique Biotechnology from one of the existing shareholders, Shenzhen Webio, for a cash consideration of RMB14m (approximately $2m).

At 9:16am: [LON:CTI] Cathay International Holdings Ltd share price was 0p at 7.5p

Story provided by